SCHEMBL6086450

SCHEMBL6086450

Cc1c(Cl)cccc1C(=O)Nc1ccc(-c2n[nH]cc2-c2nc3cc(Cl)ccc3o2)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.59
POLB P06746 2/20 0.59
KDM4E B2RXH2 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
THRB P10828 3/20 0.54
TP53 P04637 6/20 0.53
CETP P11597 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
PTGS2 P35354 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
PTGES O14684 1/20 0.51
CEPT1 Q9Y6K0 1/20 0.51
NPC1 O15118 1/20 0.50
CASP3 P42574 1/20 0.50
RAB9A P51151 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084108 0.91 MAPT (0.52) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6086535 0.84 TP53 (0.61) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6085050 0.84 MAPT (0.60) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6086038 0.82 GLA (0.53) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6084729 0.82 MAPT (0.60) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6083652 0.82 MAPT (0.68) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6084901 0.81 POLB (0.62) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6084979 0.81 MAPT (0.57) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6087376 0.81 PTGS2 (0.51) MAPTPOLBKDM4ENPSR1THRB
SCHEMBL6086246 0.81 TP53 (0.56) MAPTPOLBKDM4ENPSR1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885POLB 1679/4885KDM4E 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.